Vision Research & Clinical Trials Havener Eye Institute Jenna Rajczyk Demarcus Williams 13 April 2018
|
|
- Rosanna Haynes
- 5 years ago
- Views:
Transcription
1 Vision Research & Clinical Trials Havener Eye Institute Jenna Rajczyk Demarcus Williams 13 April 2018
2 Our Journey to Clinical Research
3 Types of Research Animal Behavioral Basic/Fundamental Translational Clinical (Human Subjects)
4 4 What is Human Subjects Research?
5 What is Human Subjects Research? Research: a systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge. Human subject: a living individual about whom an investigator (whether professional or student) conducting research obtains (1) Data through intervention or interaction with the individual, or (2) Identifiable private information. 5
6 Human Subjects Research at Havener Eye Institute Interventional (clinical trials) Observational (clinical studies) Translational Longitudinal 6
7 Clinical Trial vs Clinical Study? Clinical Research Design No Intervention Intervention Observational Experimental Comparison Group Random Allocation Yes No Yes No Analytical study (case control, cohort) Descriptive Study Randomized Controlled Trial Non-Randomized
8 OPTHEA Clinical Trial Primary Objective To determine the efficacy of two different doses of intravitreal OPT-302 when administered in combination with Lucentis in patients with wet AMD Primary Endpoint The primary endpoint is mean change from Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA) letters.
9 Ophthalmology Clinical Trial & Public Health Implications An example: Early Treatment Diabetic Retinopathy Study (EDTRS) Primary Question: When in the course of diabetic retinopathy is it most effective to initiate treatment, specifically photocoagulation?
10 Corneal Biomechanics in Ocular Disease Study Uses various devices to define the relationship between intraocular pressure (IOP) and corneal stiffness under an applied air pulse Recruitment cohorts Healthy eye volunteers Diabetic Primary Open Angle Glaucoma Ocular Hypertension Keratoconus Age-Matched Recruitment
11 Translational Research Applies discoveries generated in the lab or preclinical studies to the development in trials and studies in humans Basic Research Clinical Research Improved Health
12 Measurements of Corneoscleral Biomechanics Using Ultrasound Developed high-frequency ultrasound imaging device Will aid in detecting and diagnosing various corneal pathology and glaucoma
13 Ocular Hypertension Treatment Study Stage 1 (1994): Determine the safety & efficacy of topical ocular hypotension medication Stage 2 (2002): Compare safety & efficacy of earlier vs later treatment in preventing Primary Open-Angle Glaucoma (POAG) Stage 3 (2015): Determine the 20-year incidence of POAG & develop a 20-year glaucoma prediction model
14 Closing Remarks
15 15 References Glaucoma Projected to Increase Significantly Due To Aging U.S. Population. (n.d.). Retrieved April 10, 2018, from Kass MA. The ocular hypertension treatment study. J Glaucoma. 1994;3(2): Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, et al. Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch Ophthalmol. 2010;128(3): Protecting Human Subjects. Protecting Human Subjects UCSF Institutional Review Board, 1 Jan. 1970, irb.ucsf.edu/. Royle P, Mistry H, Auguste P, et al. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation. Southampton (UK): NIHR Journals Library; 2015 Jul. (Health Technology Assessment, No ) Chapter 2, The landmark trials: Diabetic Retinopathy Study and Early Treatment Diabetic Retinopathy Study.Available from: Rubio, D. M., Schoenbaum, E. E., Lee, L. S., Schteingart, D. E., Marantz, P. R., Anderson, K. E., Esposito, K. (2010). Defining Translational Research: Implications for Training. Academic Medicine : Journal of the Association of American Medical Colleges, 85(3),
MEASURING THE SIZE OF A TREATMENT EFFECT: RELATIVE RISK REDUCTION, ABSOLUTE RISK REDUCTION, AND NUMBER NEEDED TO TREAT
MEASURING THE SIZE OF A TREATMENT EFFECT: RELATIVE RISK REDUCTION, ABSOLUTE RISK REDUCTION, AND NUMBER NEEDED TO TREAT Hussein Hollands, MD, MS (epid) Peter J. Kertes, MD, CM, FRCS(C) 72 The purpose of
More informationDr Taha Abdel Monein Labib Professor of Eye Surgery Cairo University.
Dr Taha Abdel Monein Labib Professor of Eye Surgery Cairo University. Although the clinical picture of glaucoma is well described, the exact mechanism leading to this specific type of damage to the optic
More informationDiagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City
Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing
More informationPresent relevant clinical findings of four landmark glaucoma trials OHTS, EMGT, CNTGS and CIGTS.
Course title: The Glaucoma Compass Course length: 1 hour +/- 31 slides Corse Description: Even with the technology and available information, glaucoma decision making can still be confusing. How should
More informationClinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME
Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment
More informationOpthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial
ASX and Media Release 3 January 2018 Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial Melbourne, Australia; January 3 2018 Opthea Limited (ASX:OPT), a late stage biopharmaceutical company
More informationClinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME
Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment
More informationCommon Causes of Vision Loss
Common Causes of Vision Loss Learning Objectives To identify the most common causes of vision loss in the United States To differentiate the most common forms of agerelated macular degeneration and diabetic
More informationLong Term Efficacy of Repeat Treatment with SLT: Seven Years Follow up
Long Term Efficacy of Repeat Treatment with SLT: Seven Years Follow up Lawrence F. Jindra, MD Columbia University Winthrop University Hospital Disclosure Speaker has independently conducted and financed
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Conversion of Ocular Hypertensives into Glaucoma: A Retrospective Study Aditi Singh 1, Shibi
More informationDiabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches
Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Dr. David Wong Associate Professor Retina Specialist, Department of Ophthalmology & Vision Sciences, University of Toronto, Canada
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal. Aflibercept for treating diabetic macular oedema.
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Aflibercept for treating diabetic macular oedema Final scope Final remit/appraisal objective To appraise the clinical and cost
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May
BRAND NAME Lucentis GENERIC NAME ranibizumab MANUFACTURER Genentech, Inc. DATE OF APPROVAL June 30, 2006 PRODUCT LAUNCH DATE July 13, 2006 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Pachymetry Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Pachymetry Professional Institutional Original Effective Date: March 11, 2004 Original Effective
More informationIRIDEX MicroPulse P3: innovative cyclophotocoagulation
Romanian Journal of Ophthalmology, Volume 61, Issue 2, April-June 2017. pp:107-111 GENERAL ARTICLE IRIDEX MicroPulse P3: innovative cyclophotocoagulation Gavris M. Monica*, Olteanu Ioana*, Kantor Erzsebet*,
More informationDiabetic Learning Event: Diabetic Eye Screening and Retinopathy- Samantha Mann & Mark Frost
Diabetic Learning Event: Diabetic Eye Screening and Retinopathy- Samantha Mann & Mark Frost Case 1 : 63 yr-old Caucasian woman with type-2 Diabetes for 8 years Ex-smoker Hypertension- 5 years FH: father
More informationAge-related macular degeneration (AMD) and RANIBIZUMAB (Lucentis)
Aggiornamento biotecnologico: MoAb anti VEGF Age-related macular degeneration (AMD) and RANIBIZUMAB (Lucentis) Giulia Germena AMD DRY (non-neovascular) Atrophic cell death in the macula No leakage WET
More informationMEDICAL POLICY SUBJECT: CORNEAL ULTRASOUND PACHYMETRY. POLICY NUMBER: CATEGORY: Technology Assessment
MEDICAL POLICY SUBJECT: CORNEAL ULTRASOUND,, PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationManagement of Neovascular AMD
Kapusta AMD Part 1 Management of Neovascular AMD Dr. Michael A. Kapusta, MD, FRCSC Ophthalmologist in Chief Jewish General Hospital Vitreoretinal Surgeon 1 FINANCIAL DISCLOSURES Consulting honoraria Bayer,
More informationAbbreviated Drug Evaluation: Fluocinolone acetonide intravitreal implant (Retisert )
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationLong-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant
Ophthalmol Ther (2015) 4:51 58 DOI 10.1007/s40123-015-0028-0 CASE REPORT Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant Thomas Bertelmann
More information2016 PQRS Recommended Measures for: Ophthalmology
Measures Groups Choose 1 Measures Group Report on a minimum of 20 eligible patients (at least 11 must be Medicare Part B FFS patients) #130: Documentation of Current Medications in the Medical Record #226:
More informationDiabetic Retinopatathy
Diabetic Retinopatathy Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Arctic DX Macula Risk Advanced
More informationDIABETIC RETINOPATHY: FROM EVIDENCE AND PROMISE TO REAL LIFE OBSERVATIONS
DIABETIC RETINOPATHY: FROM EVIDENCE AND PROMISE TO REAL LIFE OBSERVATIONS Dr. Sehnaz Karadeniz Diabetic retinopathy is one of the most feared complications of diabetes and one of the leading causes of
More informationOcular hypertension is present in approximately 8%
ORIGINAL STUDY The Probability of Glaucoma From Ocular Hypertension Determined by Ophthalmologists in Comparison to a Risk Calculator Steven L. Mansberger, MD, MPH and George A. Cioffi, MD Objective: To
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationOcular Hypertension Treatment Study. Manual of Procedures. Version /17/2015
Ocular Hypertension Treatment Study Manual of Procedures Version 2.0 12/17/2015 Ocular Hypertension Treatment Study Manual of Procedures Version 2.0 12/17/2015 Summary of Changes Section 2.2 Section 2.3
More informationFROM OUTDATED TO UPDATED Eminence-Based Medicine
FROM OUTDATED TO UPDATED Eminence-Based Medicine Evidence-Based Medicine A REVIEW OF KEY CLINICAL TRIALS Anthony DeWilde, OD FAAO 1 EMINENCE BASED MEDICINE 2 EVIDENCE BASED MEDICINE 3 4 CLINICAL TRIALS
More informationIs There an Association of Topical Ocular Hypotensive Medication with Lens Opacification and Decreased Visual Function?
Is There an Association of Topical Ocular Hypotensive Medication with Lens Opacification and Decreased Visual Function? Supported by the National Eye Institute (EY 09307, EY 09341) National Center on Minority
More informationThe Era of anti- - - VEGF Kirk L. Halvorson, OD
The Era of anti- - - VEGF Kirk L. Halvorson, OD Introduction: Anti- - - Vascular Endothelial Growth Factor (Anti- - - VEGF) medication is a relatively a new line of medications used in treating a variety
More informationmeasure of your overall performance. An isolated glucose test is helpful to let you know what your sugar level is at one moment, but it doesn t tell you whether or not your diabetes is under adequate control
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationMarie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham. bars 2014
Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham bars 2014 Declaration of interest I have sat on Advisory boards for Novartis and Bayer Involved in Novartis sponsored
More informationClinical Trials Related to Age Related Macular Degeneration
Clinical Trials Related to Age Related Macular Degeneration Kirti Singh MD, DNB, FRCS Kirti Singh MD, DNB, FRCS, Pooja Jain MBBS, Nitasha Ahir MBBS, Divya Jain MD, DNB Guru Nanak Eye Centre, Maulana Azad
More informationOpinion 4 December 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 4 December 2013 LUCENTIS 10 mg/ml, solution for injection Vial of 0.23 ml (CIP: 34009 378 101 5 9) Applicant: Novartis
More informationVanderbilt Eye Institute Clinical Trials
April, 2010 Vanderbilt Eye Institute Clinical Trials Ophthalmology Actively Recruiting Studies For information on our clinical trials and other studies, please contact: Sandy Owings, COA, CCRP Clinic Director
More informationOphthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Ophthalmic VEGF Inhibitors Page: 1 of 5 Last Review Date: September 20, 2018 Ophthalmic VEGF Inhibitors
More informationBehandlungsstrategien beim Offenwinkelglaukom. F. Bochmann, Augenklinik LUKS
Behandlungsstrategien beim Offenwinkelglaukom F. Bochmann, Augenklinik LUKS What is strategy? what is our goal? where are we? how can we achieve our goal? Mission Statement The goal of glaucoma management
More informationVascular Disease Ocular Manifestations of Systemic Hypertension
Vascular Disease Ocular Manifestations of Systemic Hypertension Maynard L. Pohl, OD, FAAO Pacific Cataract & Laser Institute 10500 NE 8 th Street, Suite 1650 Bellevue, WA 98004 USA 425-462-7664 Cerebrovascular
More informationDiabetic Retinopathy: Managing the Extremes. J. Michael Jumper, MD West Coast Retina
Diabetic Retinopathy: Managing the Extremes J. Michael Jumper, MD West Coast Retina Case 1: EC 65 y.o. HM No vision complaints Meds: Glyburide Metformin Pioglitazone Va: 20/20 OU 20/20 Case 2: HS 68 y.o.
More informationILUVIEN IN DIABETIC MACULAR ODEMA
1 ILUVIEN IN DIABETIC MACULAR ODEMA Marie Tsaloumas Consultant Ophthalmic Surgeon Queen Elizabeth Hospital, Birmingham bars conference 2104 1 2 Declaration of interest I have sat on Advisory boards for
More informationCLASS-y Laser Treats Glaucoma
Article # 404 Comments About the Author Released: Author: Category: March 12th, 2014 Issue #0314 Ehud Assia Feature S S S S S CLASS-y Laser Treats Glaucoma Transforming complex, invasive and risky glaucoma
More informationChanges in Central Corneal Thickness over Time
Changes in Central Corneal Thickness over Time The Ocular Hypertension Treatment Study James D. Brandt, MD, 1 Mae O. Gordon, PhD, 2 Julia A. Beiser, MS, 2 Shan C. Lin, MD, 3 Monica Y. Alexander, MD, 4
More informationOcular Hypotensive Efficacy of Netarsudil Ophthalmic Solution 0.02% Over a 24-Hour Period: A Pilot Study
Ocular Hypotensive Efficacy of Netarsudil Ophthalmic Solution 0.02% Over a 24-Hour Period: A Pilot Study James H. Peace, M.D. 1, Casey K. Kopczynski, Ph.D. 2, and Theresa Heah, M.D. 2 1 Inglewood, CA 2
More informationRetinal Vein Occlusion (RVO) Treatment pathway- Northeast England. Retinal Vein Occlusion (RVO) with Macular oedema (MO)
Retinal Vein Occlusion (RVO) Treatment pathway- Northeast England (Royal Victoria Infirmary, Sunderland Eye Infirmary, James Cook University Hospital, Darlington Memorial Hospital, University Hospital
More informationThe Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care
The Common Clinical Competency Framework for Non-medical Ophthalmic Healthcare Professionals in Secondary Care Medical Retina November 2016 Association of Health Professions in Ophthalmology General basic
More informationDr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre
Dr Dianne Sharp Ophthalmologist Retina Specialists, Parnell Greenlane Clinical Centre 11:00-11:55 WS #115: The Revolution in Macular Degeneration Management 12:05-13:00 WS #127: The Revolution in Macular
More informationFrom Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014
From Outdated to Updated: A Review of Important Clinical Trials in Ocular Disease from 2014 1. This course is designed to review the important ophthalmic literature that was released between October 2013
More informationSerious Eye diseases, New treatments. Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist
Serious Eye diseases, New treatments Mr. M. Usman Saeed MBBS, FRCS, FRCOphth Consultant Ophthalmologist 5 major causes of loss of vision Cataracts Glaucoma Macular degeneration Retinal Vein occlusions
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION RANIBIZUMAB (Lucentis Novartis Pharmaceuticals Canada Inc.) New Indication: Macular Edema Secondary to Retinal Vein Occlusion Recommendation: The Canadian Drug Expert Committee
More informationJose M. Martinez-de-la-Casa, Julian Garcia-Feijoo, Ana Fernandez-Vidal, Carmen Mendez-Hernandez, and Julian Garcia-Sanchez METHODS
Ocular Response Analyzer versus Goldmann Applanation Tonometry for Intraocular Pressure Measurements Jose M. Martinez-de-la-Casa, Julian Garcia-Feijoo, Ana Fernandez-Vidal, Carmen Mendez-Hernandez, and
More informationEvaluation of Changes of Macular Thickness in Diabetic Retinopathy after Cataract Surgery
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2011;25(4):238-242 DOI: 10.3341/kjo.2011.25.4.238 Evaluation of Changes of Macular Thickness in Diabetic Retinopathy after Cataract Surgery Original
More informationResearch Article http://www.alliedacademies.org/clinical-ophthalmology-and-vision-science/ A 2-year retrospective study of the treatment of retinal vein occlusion with dexamethasone 0.7 mg intravitreal
More informationNEW YORK UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF OPHTHALMOLOGY EDUCATIONAL OBJECTIVES AND GOALS
NEW YORK UNIVERSITY SCHOOL OF MEDICINE DEPARTMENT OF OPHTHALMOLOGY EDUCATIONAL OBJECTIVES AND GOALS Revision Date: 6/30/06 Distribution Date: 7/6/06 The Department of Ophthalmology at the NYU Medical Center
More informationFinancial Disclosures
Financial Disclosures DB is a scientific advisor for Regeneron/ Bayer and Genentech/ Roche & a DB member of the Regeneron Combination Products Steering Committee RCH receives grant support from Regeneron/
More informationDiabetic Retinopathy Screening Program in the Cree Region of James Bay of Quebec
RUIS McGILL VIRTUAL HEALTH AND SOCIAL SERVICES CENTRE (CvSSS) SIMPLIFYING TELEHEALTH! Diabetic Retinopathy Screening Program in the Cree Region of James Bay of Quebec Nurse and Imager Training Prepared
More informationChanges in medical and surgical treatments of glaucoma between 1997 and 2003 in France
European Journal of Ophthalmology / Vol. 17 no. 4, 2007 / pp. 521-527 Changes in medical and surgical treatments of glaucoma between 1997 and 2003 in France P.-A. KENIGSBERG PAK Santé, Paris - France PURPOSE.
More informationRole of Central Corneal Thickness in Circadian Intraocular Pressure Fluctuations among Patients with Primary Open Angle Glaucoma
Role of Central Corneal Thickness in Circadian Intraocular Pressure Fluctuations among Patients with Primary Open Angle Glaucoma Mohannad Albdour MD*, Karanjit Kooner MD, PHD** ABSTRACT Objectives: To
More informationApplications of Sustained Release Delivery Systems in Ocular Disease
Applications of Sustained Release Delivery Systems in Ocular Disease Formulation and Delivery Systems For Peptide and Protein 2012 December 5, 2012 Christopher A. Rhodes, Ph.D. Principal, Christopher A
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment
More informationThere are no published randomized, double-blind trials comparing aflibercept to other therapies in neovascular AMD.
Subject: Eylea (aflibercept) Original Effective Date: 7/11/2014 Policy Number: MCP-191 Revision Date(s): 10/11/2016 Review Date(s): 12/16/2015; 10/11/2016, 6/22/2017, 7/10/2018 DISCLAIMER This Medical
More informationEpidemiology of Major Eye Diseases Leading to Blindness in Europe: A Literature Review
Review Ophthalmic Res 212;47:171 188 DOI: 1.1159/32963 Received: November 24, 21 Accepted after revision: May 18, 211 Published online: November 26, 211 Epidemiology of Major Eye Diseases Leading to Blindness
More informationOphthalmology Unit Referral Guidelines
Ophthalmology Unit Referral Guidelines Austin Health Ophthalmology Unit holds sub-specialty sessions to discuss and plan the treatment of patients with specific ocular conditions. General including cataract
More informationEFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY
EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY Diwakar chaudhary *1, 2, Hu shuqiong, Long Yuan and Xiong kun 1 Yangtze University, 1 Nanhuan Road
More informationOptometry Student Extern Manual. Miami VA Medical Center
Optometry Student Extern Manual Miami VA Medical Center Table of contents: Rotation Description 3 Clinic Schedules 4 Absences 4 Performance Standards 5 When to check in with attending 5 References 6 Visual
More informationDiabetic Retinopathy Update 2017
Diabetic Retinopathy Update 2017 Basis for DR management standards for past 40 years Diabetic Retinopathy Study (DRS) 1971-1989 and Early Treatment of Diabetic Retinopathy Study (ETDRS) 1979-1990 Sundeep
More informationGlaucoma. Glaucoma. Optic Disc Cupping
Glaucoma What is Glaucoma? Bruce James A group of diseases in which damage to the optic nerve occurs as a result of intraocualar pressure being above the physiological norm for that eye Stoke Mandeville
More informationDiabetic Retinopathy
Diabetic Retinopathy Diabetes mellitus is one of the leading causes of irreversible blindness worldwide. In the United States, it is the most common cause of blindness in people younger than 65 years.
More informationRole of central corneal thickness measurement in management of open angle glaucoma and glaucoma suspects in Calabar, Nigeria
Original Research Article Role of central corneal thickness measurement in management of open angle glaucoma and glaucoma suspects in Calabar, Nigeria Nkanga DG 1,2, Ibanga AA 1,2, Nkanga ED 2, Etim BA
More information2017 MIPS Quality Category Measures and Benchmarks for Ophthalmology
2017 MIPS Quality Category Measures and Benchmarks for Ophthalmology Physicians must report on 50% of all patients, if reporting via registry or EHR, and 50% of all Medicare Part B patients if reporting
More informationTuberous sclerosis presenting as atypical aggressive retinal astrocytoma with proliferative retinopathy and vitreous haemorrhage
Case Report Brunei Int Med J. 2015; 11 (1): 49-53 Tuberous sclerosis presenting as atypical aggressive retinal astrocytoma with proliferative retinopathy and vitreous haemorrhage Pui Ling TANG and Mae-Lynn
More informationThe Effect of Phacoemulsification with Posterior Chamber Intraocular Lens Implantation on Intraocular Pressure and Anterior Chamber Depth
The Effect of Phacoemulsification with Posterior Chamber Intraocular Lens Implantation on Intraocular Pressure and Anterior Chamber Depth Mohammad Javad Mohamadi, MD 1 Reza Soltani Moghadam, MD 1 Hasan
More informationGlaucoma Burden in a Public Sector Hospital
Original Article Glaucoma Burden in a Public Sector Hospital P.S Mahar, M Aamir Shahzad Pak J Ophthalmol 28, Vol. 24 No. 3...............................................................................
More informationDATE: 11 March 2014 CONTEXT AND POLICY ISSUES
TITLE: Long-Term Use of Ranibizumab for the Treatment of Age-Related Macular Degeneration: A Review of the Clinical and Cost-Effectiveness and Guidelines DATE: 11 March 2014 CONTEXT AND POLICY ISSUES Age-related
More informationFDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema
Investor Update Basel, 13 August 2012 FDA approves Lucentis (ranibizumab injection) for treatment of diabetic macular edema First Major Treatment Advance in More Than 25 Years for Sight-Threatening Condition
More informationOphthalmology Macular Pathways
Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological
More informationVariability of IOP following laser photocoagulation used in the treatment of diabetic retinopathy
International Surgery Journal Agarwal S et al. Int Surg J. 2017 Oct;4(10):3433-3440 http://www.ijsurgery.com pissn 2349-3305 eissn 2349-2902 Original Research Article DOI: http://dx.doi.org/10.18203/2349-2902.isj20174511
More informationYoshiro Minami 1*, Taiji Nagaoka 2, Akihiro Ishibazawa 1,2 and Akitoshi Yoshida 2
Minami et al. BMC Ophthalmology (2017) 17:90 DOI 10.1186/s12886-017-0485-4 RESEARCH ARTICLE Open Access Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema
More informationDoes Ranibizumab Improve Best Corrected Visual Acuity in Adults with Diabetic Macular Edema Compared to Those without Ranibizumab?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2013 Does Ranibizumab Improve Best Corrected
More informationTechnology appraisal guidance Published: 27 July 2011 nice.org.uk/guidance/ta229
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion Technology appraisal guidance Published: 27 July 2011 nice.org.uk/guidance/ta229 NICE 2018. All
More informationOptometric Cataract Refined Referral
Optometric Cataract Refined Referral Guidance Notes for Optometrists Version Control: v1: April 2013 v2: August 2015 REFINED CATARACT REFERRAL PATHWAY GUIDANCE FOR OPTOMETRISTS Background Approximately
More informationGrowth Conference. October 19, May 2013
Dawson Corporate James Securities Presentation 3rd Annual Small Cap Growth Conference October 19, 2017 May 2013 Safe Harbor This document contains forward-looking statements within the meaning of the "safe
More informationJay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington
Jay M. Haynie, O.D.; F.A.A.O. Olympia Tacoma Renton Kennewick Washington I Jay M. Haynie, OD, FAAO have received honoraria from the following companies: Reichert Technologies Notal Vision Carl Zeiss Meditec
More informationMild NPDR. Moderate NPDR. Severe NPDR
Diabetic retinopathy Diabetic retinopathy is the most common cause of blindness in adults aged 35-65 years-old. Hyperglycaemia is thought to cause increased retinal blood flow and abnormal metabolism in
More informationNavilas Clinical Results: Diabetic Macular Edema Introducing a Better Treatment Paradigm for Patients and Physicians
Navilas Clinical Results: Diabetic Macular Edema Introducing a Better Treatment Paradigm for Patients and Physicians 16 % Injection-free after loading phase 65 % Injection-free after loading phase Navilas
More informationABSTRACT INTRODUCTION
DOI 10.1007/s40123-017-0114-6 ORIGINAL RESEARCH Real-World Cost Savings Demonstrated by Switching Patients with Refractory Diabetic Macular Edema to Intravitreal Fluocinolone Acetonide (Iluvien): A Retrospective
More informationOptic Disc Cupping: Four Year Follow-up from the WESDR
Investigative Ophthalmology & Visual Science, Vol. 30, o., February 989 Copyright Association for Research in Vision and Ophthalmology Optic Disc Cupping: Four Year Follow-up from the WER Barbara E. K.
More informationClinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema
Original Article Clinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema Karen Joyce G. Castro, MD, Marie Joan V. Loy, MD International Eye Institute St. Luke s Medical Center
More informationNEPTUNE RED BANK BRICK
NEPTUNE RED BANK BRICK Diabetes & The Eye Diabetics are more likely to develop Cataracts at a younger age. Diabetics are twice as likely to develop Glaucoma when compared to non-diabetics. The primary
More informationaflibercept 40mg/mL solution for injection (Eylea ) SMC No. (1074/15) Bayer
aflibercept 40mg/mL solution for injection (Eylea ) SMC No. (1074/15) Bayer 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards
More informationBuilding a Major Ophthalmic Pharmaceutical Company. Aerie Pharmaceuticals, Inc. ASRS August 8, 2016
Building a Major Ophthalmic Pharmaceutical Company Aerie Pharmaceuticals, Inc. OIS @ ASRS August 8, 2016 1 Important Information Any discussion of the potential use or expected success of our product candidates
More informationOPHTHALMOLOGICAL DISORDERS
Telephone No.: 24622495 Telegraphic Address: Aeronautical: VIDDYAYX Commercial: AIRCIVIL NEW DELHI E Mail: dri@dgca.nic.in Fax:01124629211 GOVERNMENT OF INDIA AERONAUTICAL INFORMATION SERVICE DIRECTOR
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lucentis) Reference Number: CP.PHAR.186 Effective Date: 03.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at
More informationCLINICAL SCIENCES. The Ocular Hypertension Treatment Study
CLINICAL SCIENCES The Ocular Hypertension Treatment Study Topical Medication Delays or Prevents Primary Open-angle Glaucoma in African American Individuals Eve J. Higginbotham, MD; Mae O. Gordon, PhD;
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION Contents METHODS... 2 Inclusion and exclusion criteria... 2 Supplementary table S1... 2 Assessment of abnormal ocular signs and symptoms... 3 Supplementary table S2... 3 Ocular
More informationAnti Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema
Ophthalmic Technology Assessment Anti Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular Edema A Report by the American Academy of Ophthalmology Allen C. Ho, MD, Ingrid U. Scott, MD,
More information9/25/2017 CASE. 67 years old On 2 topical meds since 3 years. Rx: +3.0 RE LE
CASE 67 years old On 2 topical meds since 3 years Rx: +3.0 /-0.5@65 RE +2.5/-0.5@115 LE IOP : 17 RE 19 LE CD: 0.5 RE 0.6 LE 1 67 years old On 2 topical meds since 3 years Rx: +3.0 /-0.5@65 RE +2.5/-0.5@115
More informationINTERQUAL PROCEDURES CRITERIA BIBLIOGRAPHY: OPHTHALMOLOGY
INTERQUAL PROCEDURES CRITERIA BIBLIOGRAPHY: OPHTHALMOLOGY BIB-1 BIB-2 InterQual PROCEDURES Criteria: OPHTHALMOLOGY McKesson Clinical Evidence Classification References cited in the clinical content are
More informationVMA at the macula resulting in VMT
Ocriplasmina for pharmacologic treatment in VMT Teresio Avitabile 1 Introduction PVD is a normal, physiologic process that occurs with aging; however, in some cases, PVD is incomplete Incomplete PVD localized
More information